Top

Published in:

01-12-2007 | Review

Recombinant human activated protein C: current insights into its mechanism of action

Authors: Marcel Levi, Tom van der Poll

Published in: Critical Care | Special Issue 5/2007

Abstract

Impairment of the protein C pathway plays a central role in the pathogenesis of sepsis. Administration of recombinant human activated protein C (rhAPC) may correct the dysregulated anticoagulant mechanism and prevent propagation of thrombin generation and formation of microvascular thrombosis. Furthermore, it may simultaneously modulate the inflammatory response. It is likely that the beneficial effect of rhAPC observed in experimental and clinical studies of severe sepsis results from a combination of mechanisms that modulate the entangled processes of coagulation and inflammation. This review presents an analysis of the various mechanisms of action of rhAPC in sepsis.

Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med. 1999, 341: 586-10.1056/NEJM199908193410807.CrossRefPubMed

Levi M, Marder VJ: Coagulation abnormalities in sepsis. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Edited by: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ. 2006, Philadelphia, PA: Lippincott, Williams and Wilkins, 1601-1613.

Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med. 1999, 340: 207-214. 10.1056/NEJM199901213400307.CrossRefPubMed

Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation. 2004, 109: 2698-2704. 10.1161/01.CIR.0000131660.51520.9A.CrossRefPubMed

Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost. 2001, 86: 51-56.PubMed

Levi M, de Jonge E, van der Poll T: Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001, 29 (Suppl): S90-S94. 10.1097/00003246-200107001-00028.CrossRefPubMed

Esmon CT: The regulation of natural anticoagulant pathways. Science. 1987, 235: 1348-1352. 10.1126/science.3029867.CrossRefPubMed

Esmon CT: The endothelial cell protein C receptor. Thromb Haemost. 2000, 83: 639-643.PubMed

Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH: Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood. 2005, 105: 1515-1522. 10.1182/blood-2004-05-1896.CrossRefPubMed

10.

Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med. 2000, 28: 2209-2216. 10.1097/00003246-200007000-00005.CrossRefPubMed

11.

Vary TC, Kimball SR: Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol. 1992, 262: C445-452.PubMed

12.

Eckle I, Seitz R, Egbring R, Kolb G, Havemann K: Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler. 1991, 372: 1007-1013.CrossRefPubMed

13.

Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986, 163: 740-745. 10.1084/jem.163.3.740.CrossRefPubMed

14.

Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001, 345: 408-416. 10.1056/NEJM200108093450603.CrossRefPubMed

15.

Garcia de Frutos P, Alim RI, Hardig Y, Zoller B, Dahlback B: Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood. 1994, 84: 815-822.PubMed

16.

Taylor FBJ, Dahlback B, Chang AC, Lockhart MS, Hatanaka K, Peer G, Esmon CT: Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood. 1995, 86: 2642-PubMed

17.

Taylor FBJ, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT: The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000, 95: 1680-1686.PubMed

18.

De Pont AC, Bakhtiari K, Hutten BA, de Jonge E, Vlasuk GP, Rote WE, Levi M, Buller HR, Meijers JC: Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol. 2006, 134: 213-219. 10.1111/j.1365-2141.2006.06127.x.CrossRefPubMed

19.

Taylor FBJ, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987, 79: 918-925. 10.1172/JCI112902.PubMedCentralCrossRefPubMed

20.

Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K: Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation. 2001, 104: 1171-1175. 10.1161/hc3501.093799.CrossRefPubMed

21.

De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL: Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med. 2006, 34: 1918-1924. 10.1097/01.CCM.0000220498.48773.3C.CrossRefPubMed

22.

Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH: Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation. 1991, 84: 2454-2462.CrossRefPubMed

23.

Gruber A, Marzec UM, Bush L, Di Cera E, Fernandez JA, Berny MA, Tucker EI, McCarty OJ, Griffin JH, Hanson SR: Relative antithrombotic and antihemostatic effects of protein C activator versus low molecular weight heparin in primates. Blood. 2007, 109: 3733-3740. 10.1182/blood-2006-07-035147.PubMedCentralCrossRefPubMed

24.

Aoki Y, Ota M, Katsuura Y, Komoriya K, Nakagaki T: Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittelforschung. 2000, 50: 809-815.PubMed

25.

Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 2001, 29: 2051-2059. 10.1097/00003246-200111000-00003.CrossRefPubMed

26.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056/NEJM200103083441001.CrossRefPubMed

27.

Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K: The protein C pathway: implications for the design of the RESPOND study. Crit Care. 2007, 11 (Suppl 5): S4-10.1186/cc6155.PubMedCentralCrossRefPubMed

28.

Laterre P-F: Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care. 2007, 11 (Suppl 5): S5-10.1186/cc6156.PubMedCentralCrossRefPubMed

29.

Fumagalli R, Mignini MA: The safety profile of drotrecogin alfa (activated). Crit Care. 2007, 11 (Suppl 5): S6-10.1186/cc6157.PubMedCentralCrossRefPubMed

30.

De Pont AC, Bakhtiari K, Hutten BA, de Jonge E, Vroom MB, Meijers JC, Buller HR, Levi M: Recombinant human activated protein C resets thrombin generation in patients with severe sepsis: a case control study. Crit Care. 2005, 9: R490-497. 10.1186/cc3774.PubMedCentralCrossRefPubMed

31.

Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004, 2: 1924-1933. 10.1111/j.1538-7836.2004.00955.x.CrossRefPubMed

32.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003, 31: 12-19. 10.1097/00003246-200301000-00002.CrossRefPubMed

33.

Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR: Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med. 2005, 33: 341-348. 10.1097/01.CCM.0000153520.31562.48.CrossRefPubMed

34.

Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, et al: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007, 176: 483-490. 10.1164/rccm.200612-1803OC.CrossRefPubMed

35.

De Pont AC, Bouman CS, de Jonge E, Vroom MB, Buller HR, Levi M: Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis. Intensive Care Med. 2003, 29: 1205-10.1007/s00134-003-1781-4.CrossRefPubMed

36.

van der Poll T, Levi M, Nick JA, Abraham E: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med. 2005, 171: 1125-1128. 10.1164/rccm.200411-1483OC.PubMedCentralCrossRefPubMed

37.

Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB: Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol. 2007, 36: 497-503. 10.1165/rcmb.2005-0425OC.PubMedCentralCrossRefPubMed

38.

39.

Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996, 87: 642-647.PubMed

40.

Hancock WW, Tsuchida A, Hau H, Thomson NM, Salem HH: The anticoagulants protein C and protein S display potent antiin-flammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc. 1992, 24: 2302-2303.PubMed

41.

Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, Salem HH: Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation. 1995, 60: 1525-1532.CrossRefPubMed

42.

White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol. 2000, 110: 130-134. 10.1046/j.1365-2141.2000.02128.x.CrossRefPubMed

43.

Levi M, Dorffler-Melly J, Reitsma PH, Buller HR, Florquin S, van der Poll T, Carmeliet P: Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood. 2003, 101: 4823-4827. 10.1182/blood-2002-10-3254.CrossRefPubMed

44.

Lay AJ, Donahue D, Tsai MJ, Castellino FJ: Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood. 2007, 109: 1984-1991. 10.1182/blood-2006-07-037945.PubMedCentralCrossRefPubMed

45.

Esmon CT: New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med. 2002, 196: 561-564. 10.1084/jem.20021088.PubMedCentralCrossRefPubMed

46.

Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002, 296: 1880-1882. 10.1126/science.1071699.CrossRefPubMed

47.

Ludeman MJ, Kataoka H, Srinivasan Y, Esmon NL, Esmon CT, Coughlin SR: PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem. 2005, 280: 13122-13128. 10.1074/jbc.M410381200.CrossRefPubMed

48.

Xu J, Qu D, Esmon NL, Esmon CT: Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem. 2000, 275: 6038-6044. 10.1074/jbc.275.8.6038.CrossRefPubMed

49.

Kurosawa S, Esmon CT, Stearns-Kurosawa DJ: The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol. 2000, 165: 4697-4703.CrossRefPubMed

50.

Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, Esmon CT: The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem. 2002, 277: 24851-24854. 10.1074/jbc.C200163200.CrossRefPubMed

51.

Feistritzer C, Sturn DH, Kaneider NC, Djanani A, Wiedermann CJ: Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol. 2003, 112: 375-381. 10.1067/mai.2003.1609.CrossRefPubMed

52.

Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ: Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003, 102: 1499-1505. 10.1182/blood-2002-12-3880.CrossRefPubMed

53.

Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J, Schildberg FW, Menger MD: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med. 2004, 32: 1011-1017. 10.1097/01.CCM.0000120058.88975.42.CrossRefPubMed

54.

Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, et al: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004, 104: 3878-3885. 10.1182/blood-2004-06-2140.CrossRefPubMed

55.

Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T, Ido M, Shimizu T, Nakagaki T, Kobayashi H, et al: Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med. 2003, 167: 1416-1426. 10.1164/rccm.200206-515OC.CrossRefPubMed

56.

Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L: Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med. 2004, 32: S302-308. 10.1097/01.CCM.0000128038.49201.8C.CrossRefPubMed

57.

Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005, 105: 3178-3184. 10.1182/blood-2004-10-3985.CrossRefPubMed

58.

Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG: Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005, 280: 17286-17293. 10.1074/jbc.M412427200.CrossRefPubMed

59.

Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003, 9: 338-342. 10.1038/nm826.CrossRefPubMed

60.

Mosnier LO, Griffin JH: Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003, 373: 65-70. 10.1042/BJ20030341.PubMedCentralCrossRefPubMed

61.

Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood. 2007, 109: 3161-3172. 10.1182/blood-2006-09-003004.CrossRefPubMed

Title: Recombinant human activated protein C: current insights into its mechanism of action
Authors: Marcel Levi
Tom van der Poll
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Critical Care / Issue Special Issue 5/2007
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc6154

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recombinant human activated protein C: current insights into its mechanism of action

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 5/2007

The safety profile of drotrecogin alfa (activated)

Introduction: severe sepsis and drotrecogin alfa (activated)

Practical aspects of treatment with drotrecogin alfa (activated)

Diagnosis and treatment of severe sepsis

Clinical trials in severe sepsis with drotrecogin alfa (activated)

The protein C pathway: implications for the design of the RESPOND study